JP Conte and his family office Lupine Crest Capital have built their deal model around structural features that fund-stage private equity sponsors cannot easily replicate. US PE deal value topped $195 billion in the first half of 2025, but that growth is concentrated into a narrow slice of large transactions. Conte’s case for patient capital in the 2026 market holds that the middle tier — where Lupine Crest actually operates — is where those structural advantages produce the most durable returns.

The first advantage is deal selection. Lupine Crest’s deal envelope sits below the level where sovereign wealth funds and continuation vehicles dominate auctions. PwC counted 47 megadeals of $5 billion or more through the first nine months of 2025 — Lupine Crest doesn’t compete for those assets by design, which keeps the firm out of the most overpriced segment of the market. The second advantage is diligence pace. Sponsor-led deals run on 60-to-90-day timelines set by lenders and exit schedules. Jean-Pierre Conte can walk away from deals that don’t meet his underwriting standards without a clock forcing a decision.

The third advantage is hold-period flexibility. PwC notes that the median age of exited companies in H1 2025 sat around six years, with PE firms still carrying assets from 2017 and 2018 vintage funds. Family offices that bought at the same vintage held longer without being forced to sell. The LP obligations that pressure fund-stage sponsors into exit timelines don’t apply to Lupine Crest Capital, because there are no redemption windows to manage. Sellers who need execution certainty know which buyers actually close — and that seller-side trust creates ongoing deal access that fund-stage sponsors can’t replicate.

Lupine Crest invests across private equity, real estate, and venture, with a middle-market focus on healthcare, financial services, software, and industrial technology. JP Conte’s multi-decade career across capital cycles and his team’s long sector tenure are what build the seller relationships that fund-stage sponsors, cycling deal teams on a fund-by-fund basis, can’t sustain. His board service at the UCSF Foundation reflects the same long-range commitment he brings to capital allocation at Lupine Crest.